Slide 1: Investor Presentation: Q4 & FY25
Investor Presentation: Q4 & FY25 May, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 3: Executive Chairman’s Message
Executive Chairman’s Message “For the financial year 2025, we achieved revenue of Rs 1860 Cr, and EBITDA stood at Rs 328 Cr with EBITDA margin of 17.7%. In FY25, we delivered positive financial performance. Our results reflect a clear alignment to positive global trends — particularly the shift towa
Slide 4: Quarterly Financials Highlights
Quarterly Financials Highlights 4
Slide 5: Q4 FY25: Operational Highlights
Q4 FY25: Operational Highlights Revenue EBITDA PAT EBITDA Margin EPS Rs. 552 Crore Rs. 123 Crore Rs. 50 Crore 22.4 % Rs. 4.1 YoY 7% YoY 31% YoY 49% YoY 402 bps YoY 49% QoQ 23% QoQ 71% QoQ 192% QoQ 623 bps QoQ 192% 55
Slide 6: Q4 FY25: Consolidated Performance
Q4 FY25: Consolidated Performance Rs. In crores Revenue EBITDA EBITDA% COMMENTARY • Board has recommended a final dividend of 40% of FV • Better product mix supported by business excellence initiatives, led • Revenue recorded at Rs 552 Crore to strong improvement in margins • In pharmaceutical busin
Slide 7: Q4 FY25: Pharmaceuticals Performance
Q4 FY25: Pharmaceuticals Performance Rs. In crores Revenue EBIT COMMENTARY • Our API business continues to strengthen geographical • In Animal Health business we have completed presence and expand product portfolio validation of 8 products • Registrations continues to come through in regulated marke
Slide 8: Q4 FY25: Crop Protection Performance
Q4 FY25: Crop Protection Performance Rs. In crores Revenue EBIT COMMENTARY • We witnessed volume recovery however margins remain under • The Crop Protection industry is undergoing strategic realignments pressure leading to near term challenges • CDMO business has a robust pipeline of 8 projects from
Slide 9: Q4 FY25: Revenue Contribution
Q4 FY25: Revenue Contribution Segment Revenue Split Pharmaceuticals: Revenue Split 42% Q4 51% Q4 58% FY24 49% FY25 66% 64% Crop Protection: Revenue Split 34% 36% 22% 38% Q4 Q4 FY24 FY25 62% Q4FY24 Q4FY25 78% Pharmaceuticals Crop Protection CDMO Own products 99
Slide 10: Q4 FY25: Consolidated P&L
Q4 FY25: Consolidated P&L Particulars (Rs. In crores) Q4FY25 Q4FY24 YoY Q3FY25 QoQ Revenue 552.4 514.0 7% 447.7 23% Expenditure 428.9 419.7 375.5 EBITDA 123.5 94.3 31% 72.2 71% EBITDA Margin 22.4% 18.3% 410 bps 16.1% 630 bps Other Income 0.5 0.5 3.6 Depreciation 37.7 32.3 33.2 Interest 17.9 15.3 18.
Slide 11: Full Year Financials Highlights
Full Year Financials Highlights 11
Slide 12: Yearly Financial Highlights
Yearly Financial Highlights Rs. In crores Revenue EBITDA PAT 12
Slide 13: Yearly Segmental Highlights
Yearly Segmental Highlights Rs. In crores Pharmaceuticals Revenue Crop Protection Revenue Pharmaceuticals EBIT Crop Protection EBIT 13
Slide 14: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO Own Products 14
Slide 15: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. In Crore) FY25 FY24 Y-o-Y Net Sales 1,860 1,785 4% Expenditure 1,532 1,518 EBITDA 328 267 23% EBITDA Margin 17.7% 15.0% +270 bps Other Income 5 2 Depreciation 134 118 Finance Costs 75 56 PBT 124 95 30% Tax 33 26 Net Profit 91 70 31% 15
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. In Crore) Mar-25 Mar-24 Equities & Liabilities (Rs. Crore) Mar-25 Mar-24 Total Non Current Assets 1,534 1,520 Shareholders Fund 1,263 1,188 Property, Plant and Equipment 1293 996 Share Capital 25 25 Capital work in Progress 121 414 Other Equity 1,238 1,163 Righ
Slide 17: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In Crore) Full Year ended 31-Mar-25 Full Year ended 31-Mar-24 Profit before tax 124 95 Adjustments 215 175 Operating Profit Before Working Capital Changes 339 270 Change in operating assets and liabilities (29) (53) Cash generated from operations 310
Slide 18: Ratio Analysis
Ratio Analysis ROE% ROCE% Net Debt / Equity (x) Net Debt / EBITDA (x) 18
Slide 19: About Us
High Resolution Image needed About Us
Slide 20: Our Vision & Mission
Our Vision & Mission VISION MISSION To be the leading global fine To create value through superior, chemical company to the chemical products and operate as a Pharmaceutical, Crop Protection, responsible company. Building trust We have a strong presence across multiple segments with a and Specialty
Slide 21: Key Milestones
Key Milestones 1988 1991 1995 1997 Founded by Jai Hiremath as a First Plant site set up in Listed on Bombay Stock Taloja plant commissioned for chemical business Mahad, Maharashtra Exchange & National Stock CDMO Project with US Innovator Exchange 2009 2001 2000 New R&T Centre established & Tokyo Acq
Slide 22: Domestic & Global Presence
Domestic & Global Presence We Service Clients Globally Through our Global Footprint Panoli Taloja Europe USA Japan Pune India Navi Mumbai Bengaluru Mahad Corporate HQ R&T center, Integrated Mini Plant Manufacturing Site We serve markets across Americas, Europe, ME & We have offices across USA, Europ
Slide 23: Manufacturing Capabilities
Manufacturing Capabilities Pharmaceuticals Jigani Unit 1, Karnataka Jigani Unit 2, Karnataka Panoli, Gujarat • US FDA Approved API and Advanced Intermediates • Scale-up and Launch Plant • Acquired Manufacturing site from Novartis in 2000 Manufacturing Site • Multipurpose and Multi-product cGMP Facil
Slide 24: Our state-of-the-art R&T facility
Our state-of-the-art R&T facility 15 4 1 Synthetic Instrumentation Kilo Lab Laboratories Labs (Scale up & Pilot) 1 1 1 Process Effluent Solid State Safety Treatability Chemistry Lab Lab Lab 1 1 1 Innovation Simulation High Lab Lab Pressure Lab 6 >250 26 Process Post PhD Development Lab Graduates 24
Slide 25: Key Operational Metrics
Key Operational Metrics 5 $60Mn 3000+ 24 Manufacturing facilities Capex invested in new Assets Employees Production Blocks Pharmaceuticals Crop Protection 67 27 2,460MT 1 Kilo lab 22 3,740MT Active DMFs Commercialized Active P h a r m a (Scale up & Pilot) Commercialized Active Ingredients APIs Ingre
Slide 26: Sustainability Initiatives
Sustainability Initiatives
Slide 27: ESG Strategy
ESG Strategy E nvironment Decarbonization Material circularity Water management S ocial Community Health and safety Diversity & inclusion Employee relations Customers G overnance Governance Transparency & risk Fair sourcing & corruption management Note: * Resource Intensity 27
Slide 28: ESG – Key Initiatives
ESG – Key Initiatives PHASE 1 PHASE 2 PHASE 3 Initiation Program (Completed) Program Governance (Completed) Actions & Impact (Ongoing) • Baselining for GHG1&2 • Baselining for GHG Scope 3 • Submission SBTi Targets • Material Topics Identification • Signatory to SBTi • Deployment of Energy saving Pro
Slide 29: Regulatory Approvals
Regulatory Approvals Integrated Management Key Regulatory Approvals Systems across all sites 29
Slide 30: Awards
High Resolution Image needed Awards
Slide 31: Awards & Accolades
Awards & Accolades Our Corporate Communications & Digital team awarded Our Chairman recognised by WWF India for with the Bronze Award for Excellence in Environmental Hikal’s impactful contribution towards Nature Stewardship at the Imagexx 2024 Summit Awards for Gaudian Program Hikal's #PledgeForGree
Slide 32: Thank You
Thank You Company: Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Ms. Ami Parekh Kuldeep_jain@hikal.com +91-9920602034 / +91-8082466052 jigar.kavaiya@sgapl.net/ ami.parekh@sgapl